FDA-Approved Prescription Weight Loss Pills: A Comprehensive Guide

For adults managing obesity, the landscape of pharmacological treatment has expanded to include several FDA-approved oral medications designed to be used alongside a lower-calorie diet and regular physical activity. These options range from traditional appetite suppressants to newer GLP-1 agonists and lipase inhibitors, each operating through different biological mechanisms to facilitate weight loss.

Selecting the appropriate medication requires a detailed medical history and a clear understanding of a patient’s specific goals. Recommending an appropriate anti-obesity medication requires collecting a thorough history from each patient, including an understanding of their weight loss goals and expectations, says Kyle J. Thompson, MD, a bariatric and weight loss surgeon at Intermountain Health in Denver.

GLP-1 Agonists and New Oral Options

Recent approvals have introduced oral versions of glucagon-like peptide-1 (GLP-1) agonists, which mimic a hormone produced by the small intestine. These drugs increase satiety by affecting brain regions that process hunger and by slowing the rate at which the stomach empties.

Oral semaglutide (Wegovy) was approved by the U.S. Food and Drug Administration (FDA) in December 2025 for adults with obesity and at least one related health condition. In clinical trials, participants using oral semaglutide lost an average of 13.6 percent of their total body weight over approximately 15 months. The medication is also used to reduce the risk of major cardiovascular events, such as stroke and heart attack, in adults who are overweight or have obesity and heart disease.

Wegovy requires a strict administration protocol: a daily morning dose taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before consuming food, drink, or other medications. This regimen can be a barrier to real-world success. Auda Auda, MD, a board-certified family medicine physician at Baker Health in New York City, notes that oral semaglutide often falls short outside of trials because adherence and side effects become limiting factors, describing it as the most challenging of these pills due to the timing and fasting requirements.

Another oral GLP-1 option, orforglipron (Foundayo), was approved in April for adults with obesity or those who are overweight with weight-related health issues. As a small-molecule drug, Foundayo is absorbed into the bloodstream regardless of food or drink consumption, removing the fasting restrictions associated with peptide-based drugs like semaglutide. In trials, adults with obesity but without diabetes lost an average of 7.8 to 12.4 percent of their body weight over 72 weeks, compared to 0.9 percent in the placebo group.

Combination Medications and Appetite Suppressants

Other prescription options combine different active ingredients to target weight loss from multiple angles. Phentermine and topiramate (Qsymia) is an extended-release capsule that reduces appetite and hunger. In clinical trials, the highest dose (15 mg of phentermine and 92 mg of topiramate) resulted in an average weight loss of 9.8 percent after one year, while the placebo group lost 1.2 percent.

Naltrexone and bupropion (Contrave) is another combination therapy available as an extended-release capsule. It is thought to affect brain areas that control hunger, helping users feel fuller and burn more calories. Clinical trial participants on the maximum dose (32 mg of naltrexone and 360 mg of bupropion) lost an average of about 6 percent of their total body weight after one year, compared to 1.4 percent for the placebo group.

Contrave uses a gradual titration schedule over four weeks to reach its full dose. Dr. Auda suggests this medication may be a strong option for those struggling with emotional eating or cravings, provided they can adhere to the twice-daily dosing schedule.

Older appetite suppressants, such as phentermine and diethylpropion, help users feel full faster. While these medications never received FDA approval for long-term use, some specialists prescribe them chronically if the patient is not experiencing safety problems and the drug remains effective.

Lipase Inhibitors and Over-the-Counter Options

Orlistat, available as both a nonprescription (Alli) and prescription (Xenical) drug, works as a lipase inhibitor. It prevents the intestines from absorbing some of the fat found in food. Clinical trials using prescription-strength orlistat (120 mg three times daily) showed an average weight loss of about 13 pounds, or 5 to 6 percent of body weight, after four years, compared to 6.5 pounds in the placebo group.

Despite the weight loss, Dr. Thompson notes that orlistat is poorly tolerated by many patients due to the gastrointestinal effects, and patients often find that the benefits do not outweigh the side effects.

Regarding over-the-counter supplements—including botanicals like African mango and hoodia, caffeine pills, and tea extracts—medical experts urge caution. Dr. Auda warns that most of these products contain undisclosed stimulants or ingredients with no proven benefit. Instead, he recommends evidence-based support such as fiber, protein, electrolytes, and hydration to support metabolism.

Safety, Side Effects, and Contraindications

Weight loss medications frequently carry risks of gastrointestinal issues, mood changes, and other adverse effects. Common side effects vary by drug:

• Wegovy and Foundayo: Nausea, constipation, diarrhea, and vomiting.
• Contrave: Nausea, vomiting, headache, dizziness, and trouble sleeping.
• Qsymia: Mood changes, loss of voice, ear congestion, and insomnia.
• Orlistat: Loose stools, oily spotting on underwear, and stomach pain.

Certain medications are contraindicated for specific populations. Qsymia and orlistat should not be used by those who are pregnant or may become pregnant. Wegovy is not recommended for individuals with a personal or family history of medullary thyroid cancer or those with kidney or pancreas problems. Contrave is not recommended for individuals with uncontrolled hypertension, a risk of seizures, or those dependent on opioid pain medications.